|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 接受治疗的老年高血压患者的血压、抗高血压药物应用、衰弱指标与严重摔伤风险的关系显示文摘一些研究表明,降压药物、低收缩压和舒张压与跌倒风险增加相关。许多老年人表现出衰弱的指征,这可能会增加跌倒的风险。该研究纳入脑卒中地区和种族差异原因(the reasons for geographic and racial differences in stroke,REGARDS)研究中年龄≥65岁的受试者5236例,探索收缩压、舒张压、抗高血压药物类别数量以及衰弱指标与严重跌倒损伤风险的关系, | 刘莉 叶鹏 Bromfield SG Ngameni CA Colantonio LD Bowling CB Shimbo D Reynolds K Safford MM Banach M Toth PP Muntner P | 2017 | 中华高血压杂志2017，25，8： | 19 |
| 2 | 新型低密度脂蛋白胆固醇评估对全球血脂异常指南中次级靶标非高密度脂蛋白胆固醇和载脂蛋白B应用的影响显示文摘血脂异常指南通常推荐非高密度脂蛋白胆固醇(non-high-density lipoprotein-cholesterol,non-HDL-C)和载脂蛋白B(apolipoprotein B,apoB)作为主要靶点低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)的次要靶点。 | Sathiyakumar V Park J Quispe R Elshazly MB Michos ED Banach M Toth PP Whelton SP Blumenthal RS Jones SR Martin SS 刘青 叶鹏 | 2018 | 中华高血压杂志2018，26，4： | 4 |
| 3 | Ezetimibe therapy: mechanism of action and clinical update显示文摘 | Phan BA Dayspring TD Toth PP | 2012 | Vasc Health Risk Manag2012，8，2： | 1 |
| 4 | A clinician's guide to statin drug-drug interactions 显示文摘 | Kellick KA Bottorff M Toth PP | 2014 | J Clin Lipidol2014，8，： | 1 |
| 5 | Reverse cholesterol transport: high- density lipoprotein magnificent mile显示文摘 | Toth PP | 2003 | Curt Atheroscler Rep2003，5，： | 1 |
| 6 | Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease 显示文摘 | Toth PP | 2015 | Vase Health Risk Manag2015，11，11： | 1 |
| 7 | Reducing cardiovascular risk by targeting high - density lipoprotein cholesterol 显示文摘 | Toth PP | 2007 | Curr Atheroscler Rep2007，9，： | 1 |
| 8 | Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin,atorvastatin, or rosuvastatin compared with titrating statin monotherapy显示文摘 | Foody JM Toth PP Tomassini JE | 2013 | Vasc Health Risk Manag2013，9，28： | 1 |
| 9 | Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone 显示文摘 | Toth PP Urtis J | 2004 | Clin Ther2004，26，9： | 1 |
| 10 | C-reactive protein and risk of cardiovascular disease: evidence and clinical application显示文摘 | Ridker PM Bassuk SS Toth PP | 2003 | Curr Atherosclcr Rep2003，5，5： | 1 |
| 11 | Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy显示文摘 | Basile J Toth PP | 2009 | South Med J2009，102，10： | 1 |
| 12 | Comparative effects of lipid-lowering therapies 显示文摘 | Davidson MH Toth PP | 2004 | Progress in Cardiovascular Diseases2004，47，2： | 1 |
| 13 | High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies 显示文摘 | Toth PP | 2005 | Am J Cardiol2005，96，9： | 1 |
| 14 | Reverse cholesterol transport: high -density lipoprotein's magnificent mile 显示文摘 | Toth PP | 2003 | Curr Atheroscler Rep2003，5，： | 1 |
| 15 | Therapeutic interventions targeted at the augmentation of reverse cholesterol transport显示文摘 | Toth PP Davidson MH | 2004 | Curr Opin Cardiol2004，19，4： | 1 |
| 16 | C-reactive protein and risk of cardiovascular disease: evidence and clinical application 显示文摘 | Ridker PM Bassuk SS Toth PP | 2003 | Curr Atheroscler Rep2003，5，5： | 1 |
| 17 | Lipoprotein-associ- ated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker显示文摘 | Toth PP McCullough PA Wegner MS | 2010 | Expert Rev Cardiovasc Ther2010，8，3： | 1 |
| 18 | High-density lipoproteins: marker of cardiovascular risk and therapeutic target 显示文摘 | Toth PP Davidson MH | 2010 | J Clin Lipidol2010，4，5： | 1 |
| 19 | Reverse cholesterol transPort : high - density lipoprotein magnificent mile显示文摘 | Toth PP | 2003 | Curt Atheroscler ReP2003，5，5： | 1 |
| 20 | An update on the benefits and risks of rosuvastatintherapy显示文摘 | Toth PP | 2014 | Postgrad Med2014，126，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员